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European Journal of Cardio-thoracic Surgery 30 (2006) 49—53AbstractObjective: To analyze the success rate of somatostatin in children with persistent chylothorax who failed dietary treatment options (fat-free
nutrition, total parenteral nutrition) and to work out predictive factors for a successful therapy with somatostatin. Methods: Retrospective
cohort study over a 5-year period (2000—2004) in a neonatal and pediatric intensive care unit of a tertiary university hospital. We analyzed the
data of 85 neonatal and pediatric patients. Treatment of chylothorax occurred according to a multistage protocol with progressing invasiveness:
(1) fat-free enteral nutrition, (2) total parenteral nutrition, (3) somatostatin infusion, (4) surgery. The percentages of patients successfully
treated at the progressing steps were recorded. The somatostatin group was analyzed regarding to physiologic, diagnostic, treatment and
outcome parameters. Somatostatin-responders were compared with non-responders. Results: Seventy-six of the 85 patients had chylothorax
after cardiac surgery. Sixty-six percent could be treated with fat-free nutrition alone, 19% needed treatment with total parenteral nutrition and
in 15% somatostatin was added. Of the whole sample, 4.7% required a surgical intervention. Of the 13 patients treated with somatostatin, all had
bilateral chylothorax. Six patients (46%) responded to somatostatin. Responders and non-responders did not differ significantly regarding age, day
of postoperative diagnosis of chylothorax, amount of chylous effusion before somatostatin infusion, triglyceride concentration and lymphocyte
percentage in chylous, and central venous pressure (p = 0.066). Conclusions: Somatostatin, integrated in a treatment algorithm, was successful
in resolving persistent chylothorax in around 50% of patients. With this strategy, some children may be prevented from undergoing an operation.
However, factors predicting successful therapy with somatostatin could not be elicited.
# 2006 Elsevier B.V. All rights reserved.
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Chylothorax, an accumulation of lymphatic fluid in the
pleural space, is still a severe disease after cardiac or
thoracic surgery and an important factor for length of stay in
pediatric intensive care units [1]. The incidence of post-
operative chylothorax is between 0.25% and 5.3% [1—3]. The
congenital form of chylothorax is uncommon, but the most
frequent reason for pleural effusion in the neonatal period
and often associated with other malformations [4,5]. Other
reasons for chylothorax are thrombosis of the subclavian
vein, congenital anomalies, lymphangiectasis, injuries of
the thoracic duct and tumors. Increased central venous
pressure and, rarely, lymphatic vessel malformation in
patients with dysmorphic syndromes may aggravate the
pleural effusion.* Corresponding author. Tel.: +41 44 266 7053.
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doi:10.1016/j.ejcts.2006.03.039The standard treatment of chylothorax in pediatric and
neonatal intensive care includes conservative therapy with
fat-free or medium chain triglyceride nutrition (MCT), total
parenteral nutrition and, if this is not successful, surgical
interventions (pleurodesis, ligation of the duct, pleuro-
peritoneal shunt).
In the last years several case studies reported on a new
conservative treatment option with somatostatin or soma-
tostatin analog with a high success rate [6—9]. Only two
publications reported on side effects and unsuccessful
treatment [8,9].
The acting mechanism of somatostatin in the therapy of
chylothorax is still not completely known. Recent published
data showed an effect on the splanchnic and liver blood flow
as well as a reduced lymphatic flow mediated by somatos-
tatin receptor subtypes 2, 3 and 5 [10].
However, there are still no data about the success rate of
somatostatin or analog in the treatment of chylothorax. We
analyzed the data of the patients with chylothorax during the
last 5 years treated by a predefined algorithm. We focused on
the group treated with somatostatin in order to establish
factors predictive for successful therapy.
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Fig. 1. Treatment algorithm for chylothorax. The percentages of patients reaching the progressing treatment stages are given in parentheses. MCT, median chain
triglyceride; TPN, total parenteral nutrition.2. Materials and methods
We retrospectively studied the data of all patients with
the diagnosis of chylothorax in our pediatric and neonatal
intensive care database for the years 2000 through 2004. The
diagnosis of chylothorax was made according to the
definition of Buttiker et al. [5]: concentration of triglyceride
in pleural effusion >1.1 mmol/l and total cell count
>1000 cells/ml with predominance of >80% lymphocytes.
The patients were treated according to our hospital
guideline (Fig. 1), an algorithm with a four-step treatment
progression from fat-free nutrition to total parenteral
nutrition, somatostatin, and surgery. Somatostatin was
started at 3.5 mg/(kg h) and increased every day to a
maximal dose of 12 mg/(kg h) (Fig. 1). If somatostatin
infusion was not successful after 3 days on the maximal
dose, the infusion rate was gradually reduced over the next
3 days to zero. Successful treatment was defined as
reduction of chylous amount >50% on maximal dose. We
used a short acting form of somatostatin (Stilamin1, Serono,
Switzerland).For the patients treated with somatostatin, the following
parameters were recorded: underlying disease, type of
surgical intervention, postoperative incidence of chy-
lothorax, amount of chylous before starting somatostatin,
triglyceride level, total white cell count, percentage of
lymphocytes in the pleural effusion at the time of diagnosis of
chylothorax, duration and success rate of somatostatin
infusion. We further looked at physiologic and treatment
parameters during somatostatin infusion: central venous
pressure (median value, calculated for the days of somatos-
tatin treatment), inotropic support, suction pressure on the
pleural drainage and thrombosis. We further focused on
expected and described side effects of somatostatin like
hypo- or hyperglycemia, thyroid dysfunction, necrotizing
enterocolitis, and blood pressure variations.
The study was approved by the Hospital Ethic Committee.
Summary values are given as medians with their ranges.
Differences between groups were analyzed by Mann—
Whitney U-test or Fischer’s exact test. Statistical analysis
was done with StatView (SAS, Cary, NC). A p-value of <0.05
was considered statistically significant.
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Table 1
Underlying diseases of the patients with chylothorax (n = 85)
Diagnosis Number of patients
Congenital heart disease 76
Congenital chylothorax 3
Diaphragmatic hernia 2
Cystic adenomatoid malformation 2
Esophageal atresia 1
Lung sequester 13. Results
In the 5-year period 2000—2004 we found a total of
85 pediatric and neonatal patients with the diagnosis
of chylothorax. Seventy-six of them were post-cardiac
surgery patients. Etiology of chylothorax is summarized in
Table 1.
During this time a total of 1130 cardiac operations (with
and without heart—lung machine) were performed. Chy-
lothorax developed in 6.6% of all patients after cardiac
surgery. In this group of patients with post-cardiac surgery
chylothorax, 14 had the additional diagnosis of trisomy 21.
Chylothorax was found 31 times on the left side, 25 times
on the right side and 29 times bilaterally. Following the
hospital guidelines for the treatment of chylothorax, 56
patients (66%) could be treated with fat-free nutrition alone.
Sixteen patients (19%) needed treatment with total par-
enteral nutrition and in 13 children (15%) somatostatin was
added (Fig. 1). In the somatostatin group four patients
required pleurectomy (4.7% of the whole sample).
Three patients died in the somatostatin group. Two of
them died as a result of persistent chylothoraces beforeTable 2
Characteristics of patients treated with somatostatin (n = 13)
Diagnosis Successful
therapy with
somatostatin
Age at
diagnosis
(days)
Post
incid
chyl
(day
Coarctation No 22 3
Hypoplastic left heart syndrome Yes 13 6
Hypoplastic left heart syndrome No 302 8
Double outlet right ventricle No 14 13
Congenital Yes 1 0
Atrio-ventricular channel with
hypoplastic aortic arch, trisomy 21
No 106 22
Total anomalous pulmonary venous
return with dextrocardia
Yes 21 18
Esophageal atresia, transposition
of the great arteries, VATER association
No 10 3
d-Transposition of the great arteries Yes 23 15
d-Transposition of the great arteries,
Holt-Oram syndrome
Yes 24 20
Tetralogy of fallot No 21 15
Total anomalous pulmonary
venous return
Yes 19 15
Tetralogy of fallot, trisomy 21 No 7 5pleurectomy could be performed (non-responders). The third
patient who died was a responder: 3 weeks after successful
therapy he died following sepsis with multiorgan failure.
Table 2 shows some details of the 13 patients treated with
somatostatin. The overall success rate of the therapy with
somatostatin was 46%. In these six successfully treated
patients, the drainage could be removed at a median time of
5.5 days (range 3—13 days) after having reached the maximal
dose of 12 mg/(kg h). All of these patients had bilateral
chylothoraces.
Median age of the 13 somatostatin-treated patients at the
time of diagnosis of the chylothorax was 21 days (range 1—
302). All showed very high amounts of chylous before starting
somatostatin (median 165, range 80—278 ml/kg per day).
Side effects which were possibly related to the treatment
with somatostatin were seen in three patients: hyperglyce-
mia, hypoglycemia and transient hypothyroid function. Eight
patients were on one or more inotropes during somatostatin
infusion (Table 2).
Table 3 shows physiologic, diagnostic, treatment and
outcome parameters for responders and non-responders.
None of these parameters differed significantly between the
two groups.4. Discussion
In the present study we analyzed the data of children with
persistent chylothorax failing dietary treatment options. The
objective was to focus on patients who had been treated with
somatostatin and to find possible predictive factors for
successful therapy in the treatment algorithm for chy-
lothorax.operative
ence of
othorax
s)
Maximal
effusion before
somatostatin
(ml/kg per day)
Inotropic
support during
somatostatin
Chylothorax
relevant
venous
thrombosis
80 Dopamine,
milrinone
No
80 None No
38 None No
165 None Shunt thrombosis
256 None No
220 Adrenaline,
dopamine,
noradrenaline,
milrinone
No
178 Dopamine Left internal jugular
132 Dopamine No
278 Dopamine No
102 None Superior cava,
right internal jugular
201 Noradrenaline,
dopamine,
milrinone
No
178 Dopamine No
115 Noradrenaline,
adrenaline,
dopamine
No
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Table 3
Characteristics of infants with chylothorax responding and not responding to somatostatin treatment
Patients reacting on somatostatin (n = 6) Patients not reacting on somatostatin (n = 7) p *
Age (days) 20 (1—24) 21 (7—302) 0.72
Day of diagnosis postoperatively (days) 15 (0—20) 8 (3—22) 0.48
Maximal amount of chylothorax before
somatostatin (ml/kg per day)
178 (80—278) 132 (38—220) 0.35
Triglyceride levels in chylous (mmol/l) 3.8 (0.8—5.8) 1.2 (0.4—3.1) 0.06
Central venous pressure (mmHg) 6 (5—9) 8.5 (6—11) 0.066
Inotropic support (%) 50 71 0.59
Pleurectomy (%) 0 57 0.07
Mortality (%) 16 43 0.19
* Mann—Whitney U-test and Fisher’s exact test.Most of the patients with postoperative chylothorax
could be treated conservatively with fat-free nutrition or
total parenteral nutrition (combined 85%). This might be
due to our treatment protocol with defined treatment
progression steps. The success rate of dietary therapy alone
was slightly higher than described in the literature [11,12].
Beghetti et al. [3] published a group of 46 children with
chylothorax and a success rate of 80% with conservative
treatment. The percentage of patients with chylothorax
after cardiac surgery (6.6%) in our study is higher compared
to other publications who describe numbers of 1.5—2.3%
[3,13]. Finally, 4.6% of the patients underwent surgical
pleurectomy. This incidence was higher than that reported
by Nguyen et al. [13] for the period of 1984—1993 and may
be explained with the more complex procedures done
routinely nowadays.
A new approach for conservative management of patients
with chylothorax is the treatment with somatostatin. In our
study the application of somatostatin was successful in 46%.
So far, no data from randomized studies are available to
compare our results with. However, we did not find any
factors which influence the success of somatostatin or make
the success predictable. Only high central venous pressure
and low triglyceride level at diagnosis reached nearly
statistical significance as factors contributing to somatosta-
tin failure (Table 3). Beghetti et al. [3] mentioned that high
venous pressures (between 10 and 16 mmHg) limit the effect
of pleuro-peritoneal shunts. Although our non-responders
had much lower central venous pressures (median 8.5, range
6—11 mmHg), it is conceivable that high venous pressure may
influence the overall treatment success of chylothorax. The
lower median triglyceride level at diagnosis in the somatos-
tatin non-responders, might be due to a worse status of
enteral nutrition in these patients. Buttiker et al. [5] showed
that the triglyceride level in a chylous pleural effusion
depends on the nutrition of the patient. The presence of
thrombosis did not influence the success rate of somatosta-
tin. This was surprising because thrombosis of the subclavian
vein is a known etiologic factor of chylothorax [14—16].
The side effects in our patients might be related to the
treatment with somatostatin. Especially, the altered thyroid
function is also described in patients undergoing cardiopul-
monary bypass operations. The majority of the children
treated with somatostatin were post-cardiac surgery
patients. Therefore, it is difficult to allocate this side effect
to the somatostatin therapy. A severe side effect attributedto somatostatin, namely necrotizing enterocolitis (NEC), has
been described by Mohseni-Bod et al. [8]. However, this
patient was also suffering from a mild form of coarctation, a
well-known risk factor of NEC [17]. One out of three patients
with congenital chylothorax went on to somatostatin
treatment and he was treated with success. However, this
isolated case cannot lead to the conclusion that congenital
chylothorax should be first line treated with somatostatin.
Most of the congenital cases are resolving with conservative
treatment alone after 4—5 weeks [18].
All of our patients who were not treatable by dietary
means alone, had bilateral chylothorax. However, no factor
could be worked out to explain why some patients with
bilateral chylothorax can still be managed with fat-free
nutrition or parenteral nutrition alone.
A limitation of our study is its retrospective design. The
number of the patients treated with somatostatin is small but
nevertheless the biggest number published in the literature
so far. We started a randomized, double blind, placebo
controlled study of somatostatin treatment 5 years ago. After
having included five patients we had to stop the study
because of parental refusal. Some parents were not willing to
accept the possibility of placebo treatment with normal
saline solution in the context of complicated or desperate
clinical situations.
In conclusion, somatostatin is an option in the treatment
of persistent congenital and postoperative chylothorax. It
should be integrated in a treatment algorithm and placed
after dietary measures (fat-free nutrition, total parenteral
nutrition), but before surgical options. So applied, the
success rate of somatostatin in resolving chylothorax may be
around 50%. With this treatment regime some children with
persistent chylothorax could be prevented from undergoing
an operation.
To understand the factors that predict success, to identify
the optimal time of application and dosage of somatostatin,
and to define the characteristics of possible responders a
multicenter randomized controlled trial is required.
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